{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:37:43Z","timestamp":1790271463722,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":3354,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1038\/sj.ki.5001657","type":"journal-article","created":{"date-parts":[[2006,7,27]],"date-time":"2006-07-27T05:48:12Z","timestamp":1153979292000},"page":"1318-1324","source":"Crossref","is-referenced-by-count":284,"title":["Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of fosinopril and implications for future studies"],"prefix":"10.1016","volume":"70","author":[{"given":"F.","family":"Zannad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lehert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Gr\u00fcnfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Thuilliez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Leizorovicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lechat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"for the Fosidial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/sj.ki.5001657_bb0010","doi-asserted-by":"crossref","first-page":"A5","DOI":"10.1053\/j.ajkd.2004.10.009","article-title":"Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States","volume":"45","author":"Collins","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/sj.ki.5001657_bb0015","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ndt\/16.6.1120","article-title":"Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries","volume":"16","author":"Van Dijk","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/sj.ki.5001657_bb0020","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/ndt\/gfg233","article-title":"Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990\u20131999","volume":"18","author":"Stengel","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/sj.ki.5001657_bb0025","series-title":"USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States","author":"US Renal Data System","year":"2004"},{"key":"10.1038\/sj.ki.5001657_bb0030","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/ndt\/9.8.1136","article-title":"Comparative mortality from cardiovascular disease in patients with chronic renal failure","volume":"9","author":"Brown","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/sj.ki.5001657_bb0035","first-page":"1343","article-title":"The renal patient with coronary artery disease: current concepts and dilemmas","volume":"44","author":"Gupta","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/sj.ki.5001657_bb0040","doi-asserted-by":"crossref","first-page":"563","DOI":"10.7326\/0003-4819-137-7-200210010-00007","article-title":"Acute myocardial infarction and renal dysfunction: a high-risk combination","volume":"137","author":"Wright","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1038\/sj.ki.5001657_bb0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1468-6708-6-9","article-title":"Effect of rosuvastatin on outcomes in chronic haemodialysis patients \u2013 design and rationale of the AURORA study","volume":"6","author":"Fellstrom","year":"2005","journal-title":"Curr Control Trials Cardiovasc Med"},{"key":"10.1038\/sj.ki.5001657_bb0050","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5001657_bb0055","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1016\/j.jacc.2004.07.014","volume":"44","author":"Antman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/sj.ki.5001657_bb0060","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"The SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5001657_bb0065","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"The SOLVD Investigators","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5001657_bb0070","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","author":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","year":"1993","journal-title":"Lancet"},{"key":"10.1038\/sj.ki.5001657_bb0075","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"10.1038\/sj.ki.5001657_bb0080","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"Kober","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5001657_bb0085","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5001657_bb0090","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"The Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5001657_bb0095","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1038\/sj.ki.5001657_bb0100","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1161\/01.CIR.0000149806.01354.BF","article-title":"Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study","volume":"110","author":"Tokmakova","year":"2004","journal-title":"Circulation"},{"key":"10.1038\/sj.ki.5001657_bb0105","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1001\/archinte.162.15.1682","article-title":"Representation of the elderly, women, and minorities in heart failure clinical trials","volume":"162","author":"Heiat","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1038\/sj.ki.5001657_bb0110","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0735-1097(03)00572-2","article-title":"Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction","volume":"42","author":"Berger","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/sj.ki.5001657_bb0115","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1053\/ajkd.2002.36340","article-title":"ACE inhibitors and survival of hemodialysis patients","volume":"40","author":"Efrati","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/sj.ki.5001657_bb0120","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3317\/jraas.2002.040","article-title":"Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease","volume":"3","author":"McCullough","year":"2002","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1038\/sj.ki.5001657_bb0125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0002-9343(01)01068-3","article-title":"Renin\u2013angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients","volume":"112","author":"Knoll","year":"2002","journal-title":"Am J Med"},{"key":"10.1038\/sj.ki.5001657_bb0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2125.2000.00103.x","article-title":"Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency","volume":"49","author":"Greenbaum","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1038\/sj.ki.5001657_bb0135","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2165\/00003088-199120050-00006","article-title":"Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency","volume":"20","author":"Sica","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"10.1038\/sj.ki.5001657_bb0140","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/BF00315514","article-title":"The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients","volume":"45","author":"Gehr","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1038\/sj.ki.5001657_bb0145","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1472-8206.2002.00127.x","article-title":"FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics","volume":"16","author":"Zannad","year":"2002","journal-title":"Fund Clin Pharmacol"},{"key":"10.1038\/sj.ki.5001657_bb0150","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/(SICI)1097-0258(19990415)18:7<771::AID-SIM80>3.0.CO;2-E","article-title":"On model prespecification in confirmatory randomized studies","volume":"18","author":"Edwards","year":"1999","journal-title":"Stat Med"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815521029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815521029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T04:42:29Z","timestamp":1555735349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815521029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0085253815521029"],"URL":"https:\/\/doi.org\/10.1038\/sj.ki.5001657","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}